Biogen Inc (BIIB)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	1,632,200	1,615,200	1,158,600	1,166,600	1,161,100	1,461,800	2,664,600	3,131,000	3,046,900	2,864,700	2,059,200	1,449,700	1,556,100	1,545,800	1,918,100	3,011,700	4,000,600	5,082,400	5,926,800	5,878,800
Total stockholders’ equity	US$ in thousands	16,716,000	16,358,900	15,889,100	15,213,000	14,799,400	14,483,800	14,466,900	13,796,600	13,397,900	12,775,500	11,872,500	11,242,300	10,896,200	10,429,900	10,751,900	10,682,200	10,700,300	10,758,500	11,308,700	12,546,900
ROE		9.76%	9.87%	7.29%	7.67%	7.85%	10.09%	18.42%	22.69%	22.74%	22.42%	17.34%	12.90%	14.28%	14.82%	17.84%	28.19%	37.39%	47.24%	52.41%	46.85%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $1,632,200K ÷ $16,716,000K
= 9.76%

Biogen Inc's return on equity (ROE) has shown a declining trend over the past few years, starting at a high of 46.85% in March 2020 and gradually decreasing to 9.76% by December 2024. This indicates that the company's ability to generate profits from its shareholders' equity has been decreasing over time. The decrease in ROE may be attributed to various factors such as increasing expenses, lower net income, or inefficient utilization of the company's assets. Investors and stakeholders may view this declining trend as a cause for concern, as ROE is an important indicator of a company's financial performance and efficiency in utilizing equity capital. It is advisable for Biogen Inc to closely monitor and address the factors contributing to the decline in ROE to improve its overall financial health and shareholder returns.